
METUPUK are disappointed by the National Institute of Clinical Excellence (NICE) decision to not recommend talazoparib (Talzenna ®, Pfizer Ltd.) for treating HER2-negative, locally advanced or metastatic breast cancer with
METUPUK are disappointed by the National Institute of Clinical Excellence (NICE) decision to not recommend talazoparib (Talzenna ®, Pfizer Ltd.) for treating HER2-negative, locally advanced or metastatic breast cancer with
Sadly our Kit @Diamondtrees11 died on Monday 7th May. Her husband Phillip contacted us with the tragic news. We didn’t meet Kit but she was an integral part of METUPUK
Clinical trials are essential for testing new treatments for metastatic breast cancer. For patients, they represent hope – the chance to get access to a new potential treatment before it
Starting a new medication can be a daunting experience, especially if the medication is still fairly new to the market. Abemaciclib may not be a household name, but for those
I contacted METUPUK when I was diagnosed as a primary patient in 2018. Even though my mum died of secondary breast cancer in 2015 I had no real understanding of the metastatic disease and the challenges patients face getting access to the treatment they need.
Scientific research is vital for the development of new and improved treatments for secondary breast cancer. But what’s it like to be a scientist working in this area? Dr Hannah Harrison received her PhD in breast cancer research from the University of Manchester in 2009 and has since worked as a breast cancer research scientist in the Manchester Cancer Research Centre. Here, Hannah tells us about her work.
Oh how I wished it was a walking journey! That I could deal with! But in the last 6 months my oncologist’s quest to get me to have this PIKC3A targeted drug, was admirable, and left us on a roller coaster of emotions.
METUPUK welcomes the Scottish Medicines Consortium (SMC) decision to accept pembrolizumab (Keytruda, Merck Sharp and Dohme) plus chemotherapy (paclitaxel or nab-paclitaxel) for use on the NHS in Scotland. Pembrolizumab is
METUPUK advocate Emma Robertson spoke with ICR on pricing for cancer drugs, and gave insights into how the process can be sped up, saving more lives. The article covers the
What’s your postcode and what does that say about you? If I asked a healthy person about the importance of their postcode I suspect they’d tell me about local schools,